Honasa Consumer, the parent company of Mamaearth, is acquiring a 58% stake in nutraceutical firm Fluence Pharma for ₹135 crore. This investment marks the company's entry into the health supplements market, aiming to integrate 'inside-out' beauty solutions with its existing skincare business. The stock reacted with a decline of nearly 4% on the announcement day.
What Happened
Honasa Consumer Limited, the parent company of brands like Mamaearth and The Derma Co., has announced the acquisition of a 58% stake in Mumbai-based Fluence Pharma. The deal, valued at approximately ₹135 crore, marks Honasa's formal entry into the nutraceuticals and health supplements market. The acquisition will be housed under a newly created subsidiary named Honasa Health, which will be led by Dheeraj Nagpal, formerly associated with the nutraceutical brand Zingavita. Honasa has also outlined a plan to acquire the remaining 42% stake in Fluence Pharma in two tranches over the next 5 to 7 years.
Strategic Rationale: The 'Inside-Out' Approach
Honasa is positioning this move as a strategic expansion of its current beauty and personal care portfolio. The company intends to combine its existing topical skincare and haircare offerings with nutritional supplements, a concept it refers to as "inside-out" beauty. The goal is to provide holistic wellness solutions where supplements address hair and skin concerns from within, complementing external treatments. This strategy targets the rapidly growing Indian nutraceuticals market, which is seeing rising consumer interest in preventive health and wellness products.
Fluence Pharma's Business Profile
Fluence Pharma, founded by the Bhusari family and pharmaceutical experts Amit Bhusari and Dr. Rajendra Singh Rajput, specializes in condition-specific, over-the-counter supplements. Its platform, known as Cyclical Nutrition Therapy (CNT), uses patented formulations designed for hair and skin conditions. The company has established a significant distribution network involving over 3,000 dermatologists across India. In the financial year 2026, Fluence Pharma reported revenue of approximately ₹40 crore, with EBITDA margins exceeding 20%, indicating a profitable operational base that Honasa aims to scale using its digital-first marketing and distribution capabilities.
How The Stock Reacted
Following the announcement, shares of Honasa Consumer witnessed pressure, trading down by nearly 4% on June 24, 2026. While the company recently reported strong financial performance in Q4 FY26, investors appear to be weighing the impact of this new capital allocation. The market reaction often reflects a need to understand how quickly a new, non-core segment like health supplements can contribute to overall revenue growth and profitability compared to the established core personal care brands.
Integration and Execution Risks
For investors, the key monitorable will be the integration of Fluence Pharma into the Honasa ecosystem. While the move leverages a strong existing network of dermatologists, entering the nutraceuticals segment requires navigating different regulatory standards, supply chain requirements, and consumer buying behaviors compared to traditional skincare products. Success will depend on the management's ability to maintain Fluence Pharma's current margins while scaling its reach through Honasa's digital infrastructure. Investors will also look for clarity on how this expansion will impact the company's long-term capital allocation strategy and whether it can replicate the growth trajectory seen in its other brands.